134 related articles for article (PubMed ID: 19169960)
1. A review of contusugene ladenovec (Advexin) p53 therapy.
Senzer N; Nemunaitis J
Curr Opin Mol Ther; 2009 Feb; 11(1):54-61. PubMed ID: 19169960
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
3. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
4. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.
Gabrilovich DI
Expert Opin Biol Ther; 2006 Aug; 6(8):823-32. PubMed ID: 16856803
[TBL] [Abstract][Full Text] [Related]
5. Head and neck cancer: response to p53-based therapeutics.
Nemunaitis J; Nemunaitis J
Head Neck; 2011 Jan; 33(1):131-4. PubMed ID: 20222046
[TBL] [Abstract][Full Text] [Related]
6. Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.
Nemunaitis JM; Nemunaitis J
Future Oncol; 2008 Dec; 4(6):759-68. PubMed ID: 19086841
[TBL] [Abstract][Full Text] [Related]
7. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
8. Establishment of ponasterone A-inducible the wild-type p53 protein-expressing clones from HSC-1 cells, cell growth suppression by p53 expression and the suppression mechanism.
Hori M; Suzuki K; Udono MU; Yamauchi M; Mine M; Watanabe M; Kondo S; Hozumi Y
Arch Dermatol Res; 2009 Oct; 301(9):631-46. PubMed ID: 19009304
[TBL] [Abstract][Full Text] [Related]
9. INGN-201. Introgen Therapeutics.
Brukner I
Curr Opin Investig Drugs; 2001 Dec; 2(12):1776-85. PubMed ID: 11892946
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
Lane DP
Cold Spring Harb Symp Quant Biol; 2005; 70():489-97. PubMed ID: 16869788
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: Sch-58500, Canji.
Barnard DL
Curr Opin Mol Ther; 2000 Oct; 2(5):586-92. PubMed ID: 11249761
[TBL] [Abstract][Full Text] [Related]
12. INGN-241. Introgen.
Gopalkrishnan R
Curr Opin Investig Drugs; 2002 Dec; 3(12):1773-7. PubMed ID: 12528316
[TBL] [Abstract][Full Text] [Related]
13. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional basis for therapeutic modulation of p53 signaling.
Bassett EA; Wang W; Rastinejad F; El-Deiry WS
Clin Cancer Res; 2008 Oct; 14(20):6376-86. PubMed ID: 18927276
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Dorer DE; Nettelbeck DM
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial design for adenoviral gene therapy products.
Shirakawa T
Drug News Perspect; 2009 Apr; 22(3):140-5. PubMed ID: 19440556
[TBL] [Abstract][Full Text] [Related]
17. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
18. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway.
Tanikawa C; Furukawa Y; Yoshida N; Arakawa H; Nakamura Y; Matsuda K
Oncogene; 2009 Aug; 28(34):3081-92. PubMed ID: 19543321
[TBL] [Abstract][Full Text] [Related]
19. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
Zhang S; Li Y; Li L; Zhang Y; Gao N; Zhang Z; Zhao H
J Oral Maxillofac Surg; 2009 May; 67(5):1074-82. PubMed ID: 19375021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
